OBSV - ObsEva Has A Promising Candidate For An Unmet Need
Note: A glossary of abbreviated terms is included at the end of the article. Calculations may not appear exact due to rounding.
Investment Thesis Summary
After hitting $18.00/share in September 2018, ObsEva (OBSV) shares began a long decline and now trade under $3.00/share. Even assigning no value to IVF candidate nolasiban, which failed a phase 3 trial in November 2019, we still think the stock has been overpunished. Linzagolix is also in phase 3, and even very conservative market share assumptions point to a mispricing. The cash situation remains the biggest risk, but a partnership